Table 1.

Patient demographics and clinical characteristics

CharacteristicTotal patients (N = 52)
Sex
Male30 (58%)
Female22 (42%)
Age, y
Median52
Range24–74
Race
White49 (94%)
Asian2 (4%)
Other1 (2%)
Baseline ECOG performance status
023 (44%)
129 (56%)
Prior anti-cancer therapies, median (range)3 (1–11)
Primary tumor site and mutational status
Melanoma21
BRAF (V600)5a
NRAS2
PI3KCA1
PTEN loss1a
 No mutation3
 Unknown mutational status10
Colon/large intestine and rectum10
BRAF (V600)2
KRAS3b
PI3KCA1b
 No mutation3
 Unknown mutational status2
Ovarian6
 HRAS1
 No mutation2
 Unknown mutational status3
Lung3
BRAF (V600)1
 Unknown mutational status2
Pancreas2
KRAS1
 Unknown mutational status1
Uterus2
PI3KCA1
 No mutation1
Breast2c
Esophagus1c
Adrenal gland1c
Pleural mesothelium1c
Testicular1c
Ewing sarcoma1c
Cutaneous epidermoid carcinoma1c
  • aOne melanoma tumor contained a BRAF (V600) mutation and PTEN loss.

  • bOne CRC tumor contained a KRAS and PI3K mutation.

  • cMutational status unknown.